Wells' cellulitis and bacterial necrotizing cellulitis induced by anakinra;Cellulite de Wells et dermohypodermite bactérienne nécrosante induites par l'anakinra

Annales de Dermatologie et de Venereologie

Volumn 135, Issue 12, 2008, Pages 839-842

  Livory, M ^a   Wechsler, J ^a   Revuz, J ^a   Bagot, M ^a   Chevalier, X ^a   Poszepczynska Guigne E ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Anakinra; Eosinophilia; Wells' cellulitis

Indexed keywords

HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PENICILLIN G; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; BACTERIAL NECROTIZING CELLULITIS; CASE REPORT; CELLULITIS; FEMALE; HUMAN; INJECTION SITE REACTION; MALE; NECROSIS; POLYARTHRITIS; STREPTOCOCCUS DYSGALACTIAE EQUISIMILIS; WELLS SYNDROME;

ADRENAL CORTEX HORMONES; AGED; ANTIRHEUMATIC AGENTS; BIOPSY; CELLULITIS; EOSINOPHILIA; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; PENICILLIN G; SKIN; TIME FACTORS; TREATMENT OUTCOME; WOUND HEALING;

EID: 61349102478     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annder.2008.02.026     Document Type: Article

References (12)

1. Bresnihan B., Alvaro-Garcia J.M., Cobby M., Doherty M., Domljan Z., Emery P., et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41 (1998) 2196-2204
2. ® (anakinra) FDA briefing information, 16 August 2001.
3. Cohen S., Hurd E., Cush J., Schiff M., Weinblatt M.E., Moreland L.W., et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a 24 weeks, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002) 614-624
4. Fleischmann R.M., Schechtman J., Bennett R., Handel M.L., Burmester G.R., Tesser J., et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis. A large international, multicenter, placebo-controlled trial. Arthritis Rheum 48 (2003) 927-934
5. Wells G.C., and Smith N.P. Eosinophilic cellulitis. Br J Dermatol 100 (1979) 101-109
6. Aberer W., Konrad K., and Wolff K. Wells' syndrome is a distinctive disease entity and not a histologic diagnosis. J Am Acad Dermatol 18 (1988) 105-114
7. Koh K.J., Warren L., Moore L., James C., and Thompson G.N. Wells' syndrome following thiomersal-containing vaccinations. Australas J Dermatol 44 (2003) 199-202
8. Yagi H., Tokura Y., Matsushita K., Hanaoka K., Furukawa F., and Takigawa M. Wells' syndrome: a pathogenic role for circulating CD4+CD7- T cells expressing interleukin-5 mRNA. Br J Dermatol 136 (1997) 918-923
9. Vila A.T., Puig L., Fernãndez-Figueras M.T., Laiz A.M., Vidal D., and Alomar A. Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients. Br J Dermatol 153 (2005) 417-423
10. Bradley S.F., Gordon J.J., Baumgartner D.D., Marasco W.A., and Kauffman C.A. Group C streptococcal bacteremia: analysis of 88 cases. Rev Infect Dis 13 (1991) 270-280
11. Riente L. The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis. Reumatismo 56 (2004) 74-79
12. Fleischmann R.M., Tesser J., Schiff M.H., Schechtman J., Burmester G.R., Bennett R., et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 65 (2006) 1006-1012